The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand
\nthe treatment offerings for patients with aortic valvular heart disease worldwide. The combination of
\nSymetis\u2019 ACURATE valves with the Boston Scientific Lotus\u2122 valve platform, will also enable
\ninterventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies
\nwith two complementary and compelling technologies.<\/p>\n
Jacques R. Essinger, Ph.D. and CEO, Symetis, commented \u201cOver the past years, Symetis matured into Dominik Ellenrieder, Symetis\u2019 Chairman, added \u201cGrowing at a strong and sustained CAGR of 55% since Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.<\/p>\n","protected":false},"author":20,"featured_media":61960,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1601],"tags":[1671,1888,1437,2082,2035,1702],"_links":{"self":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/61962"}],"collection":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/comments?post=61962"}],"version-history":[{"count":0,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/posts\/61962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media\/61960"}],"wp:attachment":[{"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/media?parent=61962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/categories?post=61962"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/beta.next-finance.net\/en\/wp-json\/wp\/v2\/tags?post=61962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\na TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation.
\nThe IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means
\nto commercially expand beyond Europe and to further grow into the exciting field of structural heart. We
\nare very pleased by the positive response we received from the investment community, which we want
\nto thank for the interest it has shown in Symetis. However, as of today, the company is taking another
\npath by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional
\ncardiology will further propel Symetis\u2019 clinical excellence. As a result, we can expect more patients to
\nbe better treated for valvular heart disease globally. Moving forward, this means an exciting development
\npath for the Symetis team.”<\/em><\/p>\n
\n2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition
\nof Symetis\u2019 research and development track record in addressing patients\u2019 needs with innovative
\nstructural heart technologies, the company\u2019s manufacturing expertise and its strong relationships with
\ndoctors and healthcare professionals. We are excited about the strong potential of our combined
\nstrengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.\u201d<\/em><\/p>\n
\nby Symetis on Euronext Paris, very well received by the investment community and which was originally
\nexpected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston
\nScientific is projected to close during the second quarter of 2017, subject to customary closing
\nconditions.<\/p>\n","protected":false},"excerpt":{"rendered":"